Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport Academy medical centre, shared a post on X:
“Do you consider anti-EGFR moAbs (Cetuximab or Panitumumab) in HER2+, RAS wild-type colorectal cancer? Some preclinical data suggest that there is some degree of primary resistance to anti-EGFR therapy in HER2+ CRC (mediated by downstream activation of ERK/2 pathway).
This was also demonstrated by a large retrospective analysis (lower ORR, higher risk of progression, similar OS).”
Authors: Vincenzo Sforza, Erika Martinelli , Fortunato Ciardiello, Valentina Gambardella, Stefania Napolitano, Giulia Martini, Carminia Della Corte, Claudia Cardone, Marianna L Ferrara, Alfonso Reginelli, Giuseppina Liguori, Giulio Belli, Teresa Troiani
Authors: Tanios S Bekaii-Saab, Krzysztof Lach, Ling-I Hsu, Muriel Siadak, Mike Stecher, James Ward, Rachel Beckerman, John H Strickler
